Discontinued — last reported Q3 '20
Investing
Acquired in-process research and development
Over 3 years (FY 2021 to FY 2024), Acquired in-process research and development shows a downward trend with a -100.0% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalContext dependent
VolatilityVolatile
First reportedQ3 2020
Last reportedQ3 2020
How to read this metric
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
Detailed definition
This represents the cash outflow for the acquisition of in-process research and development projects from other entities...
Peer comparison
High in the pharmaceutical industry where external innovation is a primary driver of long-term revenue.
Metric ID:
acquired_ipr_dHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $35.00M |
| QoQ Change | — | -100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Change | — | — | — | — | -100.0% | — | — | — | — | — | — | — | — | — | — | — | — |
Range$0.00 – $35.00M
CAGR+18.1%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Product Breakdown
| Segment | Q1 '22 | Q2 '22 | Q3 '22 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|
| Mosunetuzumab | $7.10M | $7.10M | — | $7.10M | $7.10M |
| ADUHELM | — | — | $25.00M | — | — |
| Total | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Mosunetuzumab is derived from annual filings.
Acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is Biogen's acquired in-process research and development?
- Biogen (BIIB) reported acquired in-process research and development of $35.00M in Q1 2026.
- What is the long-term trend for Biogen's acquired in-process research and development?
- Over 3 years (2021 to 2024), Biogen's acquired in-process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $18.00M to $0.00.
- What does acquired in-process research and development mean?
- Cash spent to acquire research projects or drug candidates currently in development.